ProQR Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . ProQR Therapeutics BV
PRQR Stock  USD 1.99  0.03  1.49%   
ProQR Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ProQR Therapeutics' valuation are provided below:
Gross Profit
16.1 M
Profit Margin
(2.65)
Market Capitalization
212.8 M
Enterprise Value Revenue
5.8467
Revenue
16.1 M
There are over one hundred nineteen available trending fundamental ratios for ProQR Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to check out ProQR Therapeutics' recent fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 01/03/2026, Market Cap is likely to grow to about 280.2 M, while Enterprise Value is likely to drop slightly above 83.9 M.

ProQR Therapeutics Total Revenue

22.83 Million

Check ProQR Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProQR Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1.4 M, Total Revenue of 22.8 M or Research Development of 31.2 M, as well as many indicators such as Price To Sales Ratio of 12.08, Dividend Yield of 0.0 or PTB Ratio of 2.23. ProQR financial statements analysis is a perfect complement when working with ProQR Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with ProQR Stock
Check out the analysis of ProQR Therapeutics Correlation against competitors.

ProQR Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets118.7 M193.2 M100.9 M
Slightly volatile
Short and Long Term Debt Total19.5 M19.8 M15.9 M
Slightly volatile
Other Current Liabilities39.5 M37.6 M11.9 M
Slightly volatile
Total Current Liabilities47 M44.7 M16.3 M
Slightly volatile
Accounts Payable13.7 K14.4 K427.7 K
Very volatile
Cash102.1 M171.8 M87.1 M
Slightly volatile
Non Current Assets Total8.9 M16.2 M7.7 M
Slightly volatile
Long Term Debt9.9 M4.9 M7.5 M
Slightly volatile
Cash And Short Term Investments102.1 M171.8 M87.1 M
Slightly volatile
Net Receivables2.2 M2.3 M4.3 M
Pretty Stable
Common Stock Total Equity1.3 M2.5 M1.3 M
Slightly volatile
Common Stock Shares Outstanding98.6 M93.9 M44.2 M
Slightly volatile
Liabilities And Stockholders Equity118.7 M193.2 M100.9 M
Slightly volatile
Non Current Liabilities Total29.1 M46.6 M24.7 M
Slightly volatile
Other Stockholder Equity584.2 M556.4 M254.7 M
Slightly volatile
Total Liabilities95.9 M91.3 M42.2 M
Slightly volatile
Total Current Assets109.8 M176.9 M93.2 M
Slightly volatile
Common Stock5.2 M5 M2.1 M
Slightly volatile
Property Plant And Equipment Net9.5 M16.2 M7.6 M
Slightly volatile
Current Deferred Revenue26.5 M25.2 M6.5 M
Slightly volatile
Property Plant Equipment19.6 M18.7 M8.1 M
Slightly volatile
Inventory0.860.9312.7 K
Slightly volatile
Net Invested Capital96.2 M107.1 M72.3 M
Slightly volatile
Net Working Capital112 M132.2 M79.6 M
Slightly volatile
Capital Stock3.2 M5 M2.5 M
Slightly volatile

ProQR Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Research Development31.2 M41.8 M26 M
Slightly volatile
Cost Of Revenue145.9 K153.6 K9 M
Very volatile
Depreciation And Amortization1.7 M3.2 M1.4 M
Slightly volatile
Selling General Administrative12.8 M15.7 M10 M
Slightly volatile
Other Operating Expenses45.2 M56.8 M35.6 M
Slightly volatile
Total Operating Expenses45.2 M56.8 M35.6 M
Slightly volatile
Interest Income3.1 M2.9 M3 M
Slightly volatile
Reconciled Depreciation2.3 M3.2 M1.7 M
Slightly volatile
Selling And Marketing Expenses672.9 K757 K826.3 K
Slightly volatile

ProQR Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow98.4 M171.8 M84.4 M
Slightly volatile
Sale Purchase Of Stock44.1 M56.1 M37.3 M
Slightly volatile
Stock Based Compensation4 M2.9 M3 M
Slightly volatile
Begin Period Cash Flow92.9 M136.8 M73.2 M
Slightly volatile
Other Cashflows From Financing Activities190.7 K200.7 K1.1 M
Slightly volatile
Depreciation1.7 M3.2 M1.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Days Sales Outstanding33.4635.221.4 K
Pretty Stable
Capex To Depreciation0.560.592.4252
Slightly volatile
Inventory Turnover341325146
Slightly volatile
Days Of Inventory On Hand1.111.16191
Slightly volatile
Payables Turnover0.07410.07817.7475
Very volatile
Average Inventory3.8 K3.9 K228.9 K
Slightly volatile
Cash Per Share2.632.11.9967
Pretty Stable
Days Payables Outstanding4 K3.8 K1.2 K
Slightly volatile
Intangibles To Total Assets8.0E-48.0E-40.0216
Slightly volatile
Net Debt To EBITDA5.184.932.0054
Slightly volatile
Current Ratio4.324.558.2563
Pretty Stable
Receivables Turnover8.818.393.0169
Slightly volatile
Capex Per Share0.02980.020.0232
Very volatile
Interest Debt Per Share0.290.20.3125
Slightly volatile
Debt To Assets0.220.120.205
Slightly volatile
Operating Cycle33.4635.22858
Pretty Stable
Days Of Payables Outstanding4 K3.8 K1.2 K
Slightly volatile
Ebt Per Ebit0.770.830.9509
Pretty Stable
Long Term Debt To Capitalization0.10.110.2364
Slightly volatile
Total Debt To Capitalization0.30.190.294
Slightly volatile
Quick Ratio4.324.558.2223
Pretty Stable
Net Income Per E B T0.80.890.9818
Slightly volatile
Cash Ratio4.24.427.8387
Pretty Stable
Days Of Inventory Outstanding1.111.16191
Slightly volatile
Days Of Sales Outstanding33.4635.221.4 K
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.131.191.0482
Very volatile
Debt Ratio0.220.120.205
Slightly volatile

ProQR Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap280.2 M240.3 M252.4 M
Very volatile
Enterprise Value83.9 M88.3 M175.2 M
Slightly volatile

ProQR Fundamental Market Drivers

ProQR Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
21st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About ProQR Therapeutics Financial Statements

ProQR Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although ProQR Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in ProQR Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on ProQR Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue25.2 M26.5 M
Total Revenue21.7 M22.8 M
Cost Of Revenue153.6 K145.9 K
Stock Based Compensation To Revenue 0.13  0.12 
Sales General And Administrative To Revenue 0.83  0.79 
Research And Ddevelopement To Revenue 2.21  2.10 
Capex To Revenue 0.09  0.08 
Revenue Per Share 0.27  0.28 
Ebit Per Revenue(1.45)(1.52)

Pair Trading with ProQR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProQR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against ProQR Stock

  0.79TRV The Travelers CompaniesPairCorr
  0.71AMGN Amgen IncPairCorr
  0.62MRK Merck CompanyPairCorr
  0.59XOM Exxon Mobil Corp Aggressive PushPairCorr
  0.58FTV Fortive CorpPairCorr
The ability to find closely correlated positions to ProQR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProQR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProQR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProQR Therapeutics BV to buy it.
The correlation of ProQR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProQR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProQR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProQR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for ProQR Stock Analysis

When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY